BridgeMD
New treatment option for Acute Chest Pain
Official title Intravenous Hydromorphone for the Treatment of Acute Pain
ClinicalTrials.gov ID: NCT06949059
What this study is testing
What is Hydromorphone?
Hydromorphone is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for acute chest pain.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To observe the efficacy and safety of hydromorphone in the treatment of acute chest pain, and to explore the potential advantages of hydromorphone for analgesia in patients with acute chest pain, so as to provide more theoretical basis for individualized analgesia and rapid recovery in patients with acute chest pain.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 64
You may be able to join if
- Age 18-64 years old;
- Gender is not limited;
- Patients with acute chest pain, with the time from pain onset to visit the doctor ≤ 24 days;
- Severe pain that requires the use of opioids to control as determined by emergency physicians;
- Obtain informed consent from the patient or family members.
You likely can't join if
- Known allergy to hydromorphone or morphine;
- Systolic blood pressure \<100 mmHg, oxygen saturation \<95%, pulse less than 60 beats/min;
- Use of acetaminophen or nonsteroidal anti-inflammatory drugs in the past 8 hours;
- Chronic pain, defined as pain lasting for more than 12 weeks;
- Delirium, alcohol withdrawal symptoms or other drug intoxication;
- Pregnant or lactating women;
See the full eligibility criteria
- Age 18-64 years old;
- Gender is not limited;
- Patients with acute chest pain, with the time from pain onset to visit the doctor ≤ 24 days;
- Severe pain that requires the use of opioids to control as determined by emergency physicians;
- Obtain informed consent from the patient or family members.
- Known allergy to hydromorphone or morphine;
- Systolic blood pressure \<100 mmHg, oxygen saturation \<95%, pulse less than 60 beats/min;
- Use of acetaminophen or nonsteroidal anti-inflammatory drugs in the past 8 hours;
- Chronic pain, defined as pain lasting for more than 12 weeks;
- Delirium, alcohol withdrawal symptoms or other drug intoxication;
- Pregnant or lactating women;
- Patients with mental or neurological diseases, cognitive and consciousness disorders and inability to express correctly;
- Participating in any other research at the same time;
- Factors that increase the risk of participating in the study (life-threatening chest pain patients who require rapid diagnosis or treatment intervention, such as resuscitation status, excluding chest pain caused by...
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.